Arena Pharmaceuticals Earnings: Here’s Why Investors are Selling Shares Now

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 17.85%.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Arena Pharmaceuticals, Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share decreased to $-0.09 in the quarter versus EPS of $-0.18 in the year-earlier quarter.

Revenue: Rose 8.22% to $2.37 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Arena Pharmaceuticals, Inc. reported adjusted EPS loss of $0.09 per share. By that measure, the company missed the mean analyst estimate of $0.11. It missed the average revenue estimate of $50.36 million.

Quoting Management: “We are pleased with AACE’s recently published treatment guidelines and the specific reference to BELVIQ, which we believe will increase awareness among physicians and support the expansion of reimbursement,” said Jack Lief, Arena’s President and Chief Executive Officer. “We look forward to the completion of BELVIQ’s scheduling designation in the United States, and we are focused on making this new treatment option available to patients in additional parts of the world.”

Key Stats (on next page)…

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business